| About Atritech | |
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States. Mission StatementAtritech is an emerging medical device company, focused on improving the quality of life for patients with atrial fibrillation (AF) by providing a permanent alternative to medications that help reduce the risk of AF related stroke. |